¶ CHD1 — Chromodomain Helicase DNA Binding Protein 1
| Attribute |
Value |
| Gene Symbol |
CHD1 |
| Full Name |
Chromodomain Helicase DNA Binding Protein 1 |
| Chromosomal Location |
5q21.1 |
| NCBI Gene ID |
1105 |
| OMIM |
602118 |
| Ensembl ID |
ENSG00000153922 |
| UniProt |
Q86W28 |
| Protein Type |
ATP-dependent chromatin remodeler |
| Molecular Weight |
~223 kDa |
CHD1 (Chromodomain Helicase DNA Binding Protein 1) is a member of the chromodomain helicase/ATPase (CHD) family of proteins that utilize ATP to remodel chromatin structure . As an ATP-dependent chromatin remodeler, CHD1 plays essential roles in regulating gene expression by modulating nucleosome positioning, facilitating transcription factor access, and maintaining chromatin integrity . These functions are particularly critical in neurons, where precise epigenetic regulation underlies synaptic plasticity, learning, memory, and neuronal survival.
CHD1 belongs to the SNF2H family of ATP-dependent chromatin remodelers and possesses several conserved domains:
- Chromodomains: Two N-terminal chromodomains that recognize methylated histone tails, particularly H3K4me3, targeting CHD1 to promoter regions
- SANT domains: Involved in histone tail binding and chromatin interaction
- ATPase Domain: The central helicase/ATPase domain (approximately 300 amino acids) provides the energy for nucleosome sliding, eviction, and restructuring
- DNA-Binding Domains: C-terminal domains that facilitate interaction with DNA
CHD1 remodels chromatin through several mechanisms:
- Nucleosome Sliding: CHD1 can reposition nucleosomes along DNA, creating nucleosome-free regions (NFRs) at promoters and enhancers
- Nucleosome Eviction: In some contexts, CHD1 can completely remove nucleosomes to allow transcription factor binding
- Nucleosome Restructuring: CHD1 can alter nucleosome composition or replace histone variants
- Histone Exchange: CHD1 facilitates exchange of canonical histones with histone variants (e.g., H2A.Z, H3.3)
CHD1 interacts with several key cellular proteins and complexes:
- RNA Polymerase II: CHD1 associates with RNAPII throughout the transcription cycle, facilitating elongation
- Histone Acetyltransferases (HATs): Works with p300/CBP and GCN5 to coordinate transcription activation
- Histone Methyltransferases: Interacts with SETD1A/B and MLL complexes for H3K4 methylation
- SAGA Complex: Part of the SAGA coactivator complex, linking chromatin modification to transcription
CHD1 is primarily associated with active transcription:
- Promoter Clearance: Facilitates RNAPII promoter clearance and transition to productive elongation
- Elongation Control: Associates with the PAF1 complex to regulate transcription elongation
- Alternative Splicing: Influences co-transcriptional alternative splicing by affecting nucleosome positioning near splice sites
In neurons, CHD1 regulates several critical transcriptional programs:
- Synaptic Plasticity Genes: Controls expression of immediate-early genes (IEGs) like c-Fos, Arc, and Egr1 that are essential for synaptic strengthening
- Neurotrophic Factors: Regulates BDNF and other neurotrophin expression
- Ion Channel Genes: Modulates expression of voltage-gated ion channels
- Receptor Expression: Influences NMDA receptor and AMPA receptor subunit expression
CHD1 plays important roles in maintaining genomic integrity:
- Nucleotide Excision Repair (NER): Facilitates chromatin remodeling at DNA damage sites
- Transcription-Coupled Repair (TCR): Couples transcription to DNA repair, particularly important in post-mitotic neurons
- Homologous Recombination: Participates in HR repair pathways
- Base Excision Repair (BER): Supports chromatin accessibility for BER enzymes
Neurons face unique DNA repair challenges:
- Non-dividing cells: Unlike proliferating cells, neurons cannot use homologous recombination extensively
- High metabolic demand: High oxidative metabolism increases DNA damage accumulation
- Transcriptional activity: Active transcription makes neurons vulnerable to transcription-coupled DNA damage
Rare CHD1 mutations have been identified in familial ALS cases :
- Pathogenic Variants: Missense mutations in CHD1 have been found in ALS patients
- Mechanism: Mutations may disrupt chromatin remodeling and DNA repair in motor neurons
- Overlapping Pathways: CHD1 dysfunction may synergize with known ALS genes (SOD1, C9orf72, TDP-43, FUS)
CHD1 variants are associated with several neurodevelopmental conditions:
- Intellectual Disability: De novo CHD1 mutations identified in patients with intellectual disability
- Autism Spectrum Disorder (ASD): CHD1 variants found in ASD cohorts
- Developmental Delay: Variable phenotypic presentation including developmental delay
While primarily a neurological gene, CHD1 has implications in cancer:
- Prostate Cancer: CHD1 loss associated with aggressive prostate cancer
- Breast Cancer: CHD1 alterations in certain breast cancer subtypes
- Lymphoma: CHD1 mutations in some hematopoietic malignancies
CHD1 is ubiquitously expressed with high expression in:
- Brain (highest expression in neurons)
- Testis
- Embryonic stem cells
- Proliferating cells
In the brain, CHD1 is expressed throughout development:
- Developmental Expression: High expression during neurogenesis and brain development
- Adult Brain: Maintained expression in mature neurons
- Cell-Type Specificity: Primarily neuronal expression, lower in glia
CHD1 and chromatin remodelers represent potential therapeutic targets:
- BET Inhibitors: Bromodomain inhibitors may compensate for CHD1 dysfunction
- HDAC Inhibitors: Histone deacetylase inhibitors can modulate chromatin state
- Small Molecule Modulators: Development of specific CHD1 modulators is ongoing
Future therapeutic strategies may include:
- CRISPR-Based Correction: Precise correction of pathogenic CHD1 variants
- Epigenetic Engineering: Targeted epigenetic modifications to compensate for CHD1 loss
- Small Molecule Enhancers: Compounds that enhance remaining CHD1 function